Fumitaka Kikkawa
Papers
2
Total Citations
320
H-Index
2
About
Fumitaka Kikkawa is a leading figure in plasma oncology, whose pioneering work has reshaped the application of nonequilibrium atmospheric pressure plasma (NEAPP) for cancer therapy. His primary research focuses on the selective induction of apoptosis in malignant cells, particularly ovarian cancer, using cold atmospheric plasma—a novel, non-thermal technology that targets cancer cells while sparing healthy tissue. Kikkawa’s landmark 2012 study, cited over 300 times, demonstrated that NEAPP treatment could selectively kill ovarian cancer cell lines by triggering programmed cell death, while leaving normal fibroblast controls largely unharmed. This breakthrough not only highlighted the potential of plasma as a minimally invasive cancer treatment but also established a foundation for subsequent research into plasma-based oncology. His work has been instrumental in advancing the understanding of how reactive species generated by plasma can be harnessed for targeted cancer therapy, earning him recognition as a key innovator in the field. Kikkawa’s contributions continue to inspire interdisciplinary collaborations between plasma physics and clinical oncology.
Research Focus
Key Achievements
Top Papers
- 1
- 2